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Nanotechnology can provide powerful delivery carriers for cancer therapy. This 
dissertation addressed some key challenges for the development of nano-drug carriers: 
targeted therapy, multidrug resistance (MDR) and codelivery of multiple kinds of drugs. 
A variety of novel hydrogel nanoplatforms were developed for cancer therapy and 
imaging.   
Two kinds of methylene blue-conjugated polyacrylamide (PAA) nanoparticles (NPs) 
were developed for targeted photodynamic therapy, where methylene blue (MB) was the 
photosensitizer. The conjugation of MB onto NPs improved the MB loading, prevented 
any leaching of MB and avoided MB degradation due to the effects of enzymes. After 
decoration with a tumor-targeting F3 peptide, the MB-PAA NPs showed a selective cell 
killing ability towards MDA-MB-435 melanoma cells in vitro, under illumination. 
A highly engineerable hydrogel NP was developed for the optimal codelivery of a 
chemodrug, doxorubicin (Dox) and a chemosensitizer, verapamil (Vera), aiming at 
alleviating tumor MDR. The NP was based on the copolymer of acrylamide (AA) and 2-
carboxyethyl acrylate (CEA). Dox and Vera were post-loaded into the respective 
co(CEA-AA) NPs. We delivered both Dox-NPs and Vera-NPs into the Dox-resistant 




and significantly enhanced the cell killing ability of Dox with respect to NCI/ADR-RES 
cells in vitro. 
For the targeted delivery of Dox, the co(CEA-AA) NP was further conjugated with F3 
peptides via a “click reaction”. The F3 peptide targeting moieties dramatically improved 
the uptake of the NPs by the nucleolin-overexpressing glioma cell line 9L as well as by 
the drug-resistant cell line NCI/ADR-RES, correlating with nucleolin-mediated 
endocytosis. In vitro cytotoxicity results show that the Dox-F3-NPs have a stronger cell 
killing ability, towards both 9L and NCI/ADR-RES cells, than the nontargeted Dox-NPs. 
Finally, a tumor-targeted, intensely blue colored, tumor contrast agent was introduced, 
based on targeted, Coomassie Blue (CB)-linked, PAA NPs. With high loading of CB (7 
wt %), the NPs can clearly stain the tumor area, with a tolerable NP concentration. Again, 
the F3-targeted CB-PAA NPs demonstrated a better contrast delineation effect, as well as 
a longer retention time in the tumor area, in 9L-glioma bearing rats, compared to 
nontargeted CB-PAA NPs.  
 
  
 
